Brodalumab is prescribed for:
- Moderate-to-severe plaque psoriasis
- Patients who failed other systemic therapies
- Dermatologic autoimmune conditions
Blocks IL-17 receptor, affecting multiple IL-17 cytokines.
Generic Name: Brodalumab
Brand Names: Siliq
Brodalumab is an IL-17 receptor blocker for moderate-to-severe plaque psoriasis, with a boxed warning for suicidal ideation.
Brodalumab is prescribed for:
Blocks IL-17 receptor, affecting multiple IL-17 cytokines.
Common side effects:
Serious side effects:
Brodalumab blocks the IL-17 receptor, providing broader IL-17 pathway inhibition than antibodies targeting IL-17A alone.
Contains a boxed warning for suicidal ideation and behavior. Only available through a REMS program.
Despite the warning, brodalumab is highly effective, with many patients achieving complete skin clearance.
Learn more at MedlinePlus.
This medication is commonly used to treat or manage the following conditions:
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Brodalumab? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.